Management of hepatitis B and C in special population

Table 2 Hepatitis C in chronic kidney disease

	HCV and CKD
Prevalence of HCV in CKD patients	10%-14%
Pathogenesis	Pronounced leucocyte infiltration of glomerular capillaries and the precipitation of immunoglobulins, immune complexes/cryoglobulins; Glomerular deposition of HCV protein
Risk factors	Age, male gender, lack of HCV treatment, concomitant HAV/HBV infection; Diabetes mellitus
Common types of renal injury	Membranous GN; Membranoproliferative GN; Essential mixed cryoglobulinemia (type II); IgA nephropathy; Polyarteritis nodosa
Treatment indication	Viremia
Safe drugs	Glecapravir + Pibrentasvir; Sofofbuvir + Velpatasvir; Sofosbuvir + Ledipasvir; Grazoprevir + Elbasvir
Prevention	Regular screening and strict infection control procedures; Effective dialysis machine decontamination

HCV: Hepatitis C virus; CKD: Chronic kidney disease; HAV: Hepatitis A virus; GN: Glomerulonephritis.